

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Innovative Holdings Alliance, Inc.

2300 Lakeview Parkway Suite 700 Alpharetta, GA 30009

(888) 464-4424 info@ihabrands.com SIC Code 8071

Annual Report

For the period ending May 31, 2024 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

39,955,427 as of May 31, 2024

17,155,427 as of May 31, 2023

Shell Status

Yes: ⊠

,	ck mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, he Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):				
Yes:	No: ⊠				
Indicate by che	ck mark whether the company's shell status has changed since the previous reporting period:				
Yes: □	No: ⊠				
Change in Control Indicate by check mark whether a Change in Control ⁵ of the company has occurred over this reporting period:					

No:

⁴ "Change in Control" shall mean any events resulting in:

⁽i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

⁽ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

⁽iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

⁽iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Name and address(es) of the issuer and its predecessors (if any) 1)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

The company was incorporated as Auto Capital, Inc. on February 29,1996 in Nevada. The Company changed its name to Wapro, Inc. in 1999, and changed its name again in 2000 to Royal Waterlily, Inc. The company changed its name to royal Acquisitions and Development, Inc. in 2002 and then in 2008 changed its name to Innovative Health Sciences, Inc. in Nevada. Innovative Holdings Alliance, Inc.

("Company") was formed on February 24, 2011 as a wholly owned subsidiary of Innovative Health Sciences, Inc. ("Innovative Health" or "predecessor") under the laws of the State of Delaware. Innovative Health was initially formed as Auto Capital on February 29, 1996 under the laws of the State of Nevada. Effective May 27, 2011, the Company, and Innovative Health and ISHN 10, Inc. effected a plan of merger and reorganized into a Holding Company structure, whereby the Predecessor (operating company) was merged into a newly formed wholly owned subsidiary ISHN 10, Inc. of the Company pursuant to Section 251(9) of Delaware General Corporation Laws. The Company is the Holding Company successor under the Plan of Reorganization and the old operating company, ISHN 10, Inc. was divested and declared bankruptcy under Chapter 7.

Current State and Date of Incorporation or Registration: Delaware Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

Delaware

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

Address of the issuer's principal executive office:

2300 Lakeview Pkwy. Ste. 700 Alpharetta, GA 30009

Address of the issuer's principal place of business:

[] Check if principal executive office and principal place of business are the same address:

640 Belle Terre Road, Building F, Suite 2 Port Jefferson, NY 11777

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ⊠	Yes: □	If Yes, provide additional details below
<u>None</u>		

2) Security Information

Transfer Agent

Address:

Name: Pacific Stock Transfer

Phone: (702) 361-3033

Email: <u>www.pacificstocktransfer.com</u>

6725 Via Austi Pkwy. Ste. 300 Las Vegas, NV 89119

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol: <u>IHAI</u>

Exact title and class of securities outstanding: Common Stock

CUSIP: <u>457672301 (Predecessor 457670206)</u>

Par or stated value: \$0.001

Total shares authorized: 500,000,000 as of date: May 31, 2024
Total shares outstanding: 39,955,427 as of date: May 31, 2024
Total number of shareholders of record: 94 as of date: May 31, 2024

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

None

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security: Preferred Series A

CUSIP (if applicable):

Par or stated value:

\$0.00

Par or stated value: \$0.001

Total shares authorized: 500,000 as of date: May 31, 2024
Total shares outstanding (if applicable): 0 as of date: May 31, 2024

Total number of shareholders of record

(if applicable): N/A as of date: May 31, 2024

Exact title and class of the security:

CUSIP (if applicable):

Par or stated value:

Total shares authorized
Total shares outstanding (if applicable)

Total number of shareholders of record (if applicable)

N/A

Preferred Series B

N/A

\$0.001___
500,000 as of May 31, 2024

0 as of May 31, 2024

N/A

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

None

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

One vote per common share.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

The Series A Stock are entitled to no dividends and the Company has no redemptive right. The holders of the Series A Stock have the right to vote on any matter and the holders of the shares shall have the number of votes equal to that number of common shares which is not less than 60% of the vote required to approve any action.

The Series B Stock: the Company authorized 500,000 shares of \$.001 par value Series B Preferred Convertible Stock ("Series B Stock"). At the option of the holder, the shares are convertible into 100 shares of common stock for each share of Series B Stock. The holders of such Series B Stock are entitled to receive cumulative cash dividends equal to 15% of the issue price per share, payable quarterly beginning September 30, 2011 and continuing until the Series B Stock is redeemed or converted. In the event that the dividends are not paid in any period, the dividends accumulate and must be paid prior to dividends on the common stock or any other class of stock junior to the Series B Stock, except for the Series A Stock. The Company had no shares of Series B Stock issued and outstanding as of February 29, 2024 and, therefore, no dividends have been accrued. Voting is only for Series B related issues.

Describe any other material rights of common or preferred stockholders.

None

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None	

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

Shares Outstan	nding <u>Opening Baland</u>	ce:									
Date May 31, 2022 Common:16,980,427 Preferred: 500				*Right-click the rows below and select "Insert" to add rows as needed.							
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. *You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.		
M <u>ay 31</u> ,2023	<u>Canc</u> ellation	(200,000)	<u>Comm</u> on	_N/A_	NO_	<u>Steve</u> Winter	C <u>ancell</u> ation	N/A	<u>N/A</u>		
March 13, 2 <u>023</u>	<u>Issua</u> nce	3 <u>75,000</u>	Common	\$ <u>75,000</u> (<u>\$.20 per</u> <u>share)</u>	_NO_	M2Bio Sciences Food and Beverage, Ltd, Jeff Robinson	License Ag <u>reem</u> ent	Restricted	Section 4(a)(2)		
January 11, 2024	Issuance	30,000,000	Common	\$7,500,000 (\$.25 per share)	YES		Acquisition of assets	Restricted	Section 4 <u>(a)(2)</u>		
January 11, 2024	Issuance	1,000,000	Common	\$250,000 (\$.25 per share)	YES	DelVecchio	Consulting related to Premergy acquisition	Restricted	Section 4 <u>(a)(2)</u>		
January 11, 2024	Issuance	500,000	Common	\$125,000 (\$.25 per share)	YES		Legal fees related to Premergy acquisition	Restricted	Section 4 <u>(a)(2)</u>		
January 11, 2024	<u>Issuance</u>	250,000	Common	\$62,500 (\$.25 per share)	YES	William Hayde	Officer compensation	Restricted	Section 4 <u>(a)(2)</u>		
January 17, 2024	Return	(500)	Preferred	N/A	N/A	M. Chris Winter	Pursuant to agreement	Restricted	Section 4 <u>(a)(2)</u>		

January 17, 2024	<u>Return</u>	(8,950,000)	Common	<u>N/A</u>		Pursuant to agreement	Restricted	Section 4 <u>(a)(2)</u>
Shares Outstanding on Date of This Report:					•			
	Ending Ba	alance:						
Date May 31,								
Common: <u>39,9</u>	955,427 Preferred:	<u>0</u>						

Example: A company with a fiscal year end of December 31st 2023, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2022 through December 31, 2023 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: \square Yes: \boxtimes (If yes, you must complete the table below)

Use the space below to provide any additional details, including footnotes to the table above:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder. *** You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g. Loan, Services, etc.)
3.23.21	30,000	30,000	9,575	3.25.25	Convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share	NY Farms Group, Inc. Stephen Apolant, Pres. 136 Wheatly Road Brookville, NY 11545	Working Capital
3.23.21	20,000	20,000	6,384	12.31.24	Convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share	EROP Enterprises LLC. Vince Sbarra, Pres. 912 Holcomb Bridge Road Suite 101 Roswell, GA 30076	Working Capital
6.7.21	30,000	30,000	<u>8,951</u>	3.7.25	Convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share	NY Farms Group, Inc. Stephen Apolant, Pres. 136 Wheatly Road Brookville, NY 11545	Working Capital
8.27.21	40,000	40,000	11,047	2.27.25	Convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share	Seacor Capital Inc. Lisa Ficarra, Pres. 90 Sunnyside Ave. New Rochelle, NY 10804	Working Capital
10.28.21	25,000	25,000	<u>6,479</u>	2.27.25	Convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share	Seacor Capital Inc. Lisa Ficarra, Pres. 90 Sunnyside Ave. New Rochelle, NY 10804	Working Capital

^{***}Control persons for any entities in the table above must be disclosed in the table or in a footnote here.

3.30.22	25,000	25,000	5,432	3.30.25	Convertible at the sole	Seacor Capital Inc.	Working Capital
3.30.22	23,000	25,000	3,432	3.30.23	discretion of the holder at any	Lisa Ficarra, Pres.	working Capital
					time, in whole or in part, into	90 Sunnyside Ave.	
					shares of restricted common	New Rochelle, NY	
					stock at a rate of \$.01 per share	<u>10804</u>	
7.14.22	<u>35,000</u>	35,000	<u>6,588</u>	12.31.24	Convertible at the sole	Equity Markets Adv	Working Capital
					discretion of the holder at any	LLC St. 1 A 1 A D	
					time, in whole or in part, into shares of restricted common	Stephen Apolant, Pres. 136 Wheatly Road	
					stock at a rate of \$.01 per share	Brookville, NY 11545	
11.15.22	35,000	35,000	5,399	12.31.24	Convertible at the sole	Sky Direct LLC	Working Capital
					discretion of the holder at any	Stephen Apolant, Pres.	
					time, in whole or in part, into	98 Cuttermill Rd. Ste.	
					shares of restricted common	441 S Great Neck, NY	
	5 0.000	2 0.000	4.000	1	stock at a rate of \$.01 per share	11021	
3.14.23	<u>50,000</u>	50,000	6,082	3.14.25	Convertible at the sole	Sky Direct LLC	Working Capital
					discretion of the holder at any time, in whole or in part, into	Stephen Apolant, Pres. 98 Cuttermill Rd. Ste.	
					shares of restricted common	441 S Great Neck, NY	
					stock at a rate of \$.01 per share	11021	
4.28.23	20,000	20,000	2,186	10.28.24	Convertible at the sole	Seacor Capital Inc.	Working Capital
	<u> </u>				discretion of the holder at any	Lisa Ficarra, Pres.	
					time, in whole or in part, into	90 Sunnyside Ave.	
					shares of restricted common	New Rochelle, NY	
0 21 22	25.000	25,000	2.252	2 20 25	stock at a rate of \$.01 per share Convertible at the sole	DRB Consulting Inc.	Working Capital
8.31.23	25,000	<u>25,000</u>	<u>2,252</u>	<u>2.28.25</u>	discretion of the holder at any	David Behanna, Pres.	working Capital
					time, in whole or in part, into	36 Mount Grey Road	
					shares of restricted common	Setauket, NY 11733	
					stock at a rate of \$.05 per share		
1.11.24	100,000	100,000	3,863	1.11.25	Convertible at the sole	Sky Direct LLC	Working Capital
					discretion of the holder at any	Stephen Apolant,	
					time, in whole or in part, into	Pres. 98 Cuttermill	
					shares of restricted common	Rd. Ste. 441 S Great	
					stock at a rate of \$.01 per share	Neck, NY 11021	
<u>1.11.24</u>	<u>25,576</u>	<u>25,576</u>	<u>692</u>	1.11.26	Convertible at the sole	Mallory Atkinson	Pursuant to the
					discretion of the holder at any		Premergy Inc.
					time, in whole or in part, into		<u>Acquisition</u>
					shares of restricted common stock at a rate of \$.50 per share		
<u>1.11.24</u>	<u>2,000</u>	<u>2,000</u>	<u>54</u>	<u>1.11.26</u>	Convertible at the sole	Richard Botts	Pursuant to the
					discretion of the holder at any		Premergy Inc.
					time, in whole or in part, into shares of restricted common		<u>Acquisition</u>
					stock at a rate of \$.50 per share		
	1		4				
1.11.24	44,500	44,500	<u>1,203</u>	1.11.26	Convertible at the sole	<u>Lanier Davenport</u>	Pursuant to the
					discretion of the holder at any time, in whole or in part, into		Premergy Inc. Acquisition
					shares of restricted common		Acquisition
					stock at a rate of \$.50 per share		
1 11 24	2 240	2 240	62	1 11 26	_	Dlaka E-bii	Dags
1.11.24	<u>2,340</u>	<u>2,340</u>	<u>63</u>	<u>1.11.26</u>	Convertible at the sole discretion of the holder at any	Blake Fabiani	Pursuant to the Premergy Inc.
					time, in whole or in part, into		Acquisition
					shares of restricted common		11040101011
	1			<u> </u>	stock at a rate of \$.50 per share		
1.11.24	188,000	188,000	<u>5,084</u>	1.11.26	Convertible at the sole	Robert Harbin	Pursuant to the
					discretion of the holder at any		Premergy Inc.
					time, in whole or in part, into		<u>Acquisition</u>
					shares of restricted common		
1 11 24	10,000	10,000	270	1 11 26	stock at a rate of \$.50 per share Convertible at the sole	Larry C Williams	Durguent to the
1.11.24	10,000	10,000	<u>270</u>	<u>1.11.26</u>	discretion of the holder at any	484 Ivy Park Lane	Pursuant to the Premergy Inc.
					time, in whole or in part, into	Atlanta, GA 30342	Acquisition
					shares of restricted common	- IIIIII GI I 50572	11040101011
					stock at a rate of \$.50 per share		
·			•	•	· · · · · · · · · · · · · · · · · · ·	•	•

Ī	2.20.24	30,000	30,000	<u>664</u>	2.20.25	Convertible at the sole	Mohsen Khorassani	Working Capital
						discretion of the holder at any	6 Marwood Rd.	
						time, in whole or in part, into	Port Washington, NY	
						shares of restricted common	<u>11050</u>	
						stock at a rate of \$.01 per share		

^{***}Control persons for any entities in the table above must be disclosed in the table or in a footnote here.

Use the space below to provide any additional details, including footnotes to the table above:

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com).

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

On March 14, 2023, IHAI Brands, Inc. a newly formed, Delaware corporation and wholly owned subsidiary of Innovative Holdings Alliance, Inc., (the "Company") entered into a Brand License Agreement with M2Bio Sciences Food and Beverage (Pty) Ltd., ("M2Bio" or the "Licensor"). M2Bio has a range of nutritional food and beverage products that are stocked by more than 100 stores in South Africa. M2Bio also conducts research into sustainable products using primarily hemp and mycelium and is developing various cosmetics and complementary medicines using plant-based active ingredients. The Brand License gives the Company the right to be the first in the United States to market the following lines of products (the "Licensed Products"), by selling direct to consumers via its own ecommerce websites, via wholesale channels to other ecommerce and retail brick-and-mortar stores, via affiliates and influencers.

On December 30, 2023, the Company acquired all the operational assets of Premergy, Inc. ("Premergy") related to Premergy's intellectual properties ("IP") for dual/multi-chemistry battery system, adaptive energy regeneration and battery control system algorithms. These IP's s provide the end user with:

- 1. Increased vehicle range and battery efficiency in excess of 20%.
- 2. Improved thermal management and reduced battery stress resulting in improved vehicle performance and extended battery useful life.
- 3. Total charging costs ("TCO") reduced with the range improvement and adaptive energy regeneration technology.
- 4. Reduced voltage variability provides a more constant voltage out and greater efficiency.
- 5. Competitive "sticker" pricing. Reduced thermal management components lowers associated manufacturing cost.
- B. List any subsidiaries, parent company, or affiliated companies.

IHABrands, Inc.

C. Describe the issuers' principal products or services.

Food and Beverage retail products.

Licensing Premergy's IP technologies

5) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company does not own any real property. Operational office space is being provided by the CEO in Port Jefferson, NY on an as needed basis at no cost to the Company.

Effective July 1, 2024, the Company entered into a lease for virtual office space in Alpharetta GA through December 31, 2004 with an initial base rent of \$59 per month. This lease automatically renews at the end of each calendar year with a base rent of \$70 per month and may be cancelled at any time upon 30 days advance written notice after the initial lease term.

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Names of All Officers, Directors and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
William Hayde	<u>CEO</u>	Port Jefferson, NY	<u>250,000</u>	Common	Less than 1%	
Richard Botts	<u>CTO</u>	Alpharetta, GA	4.207,800 Beneficially owned as a shareholder of Premergy	Common	10.53%	
Richard Botts Shareholder Voting Trust	Owners of more than 5%	Alpharetta, GA	15,936,000 Beneficially owned as shareholders of Premergy	Common	39.88%	Richard Botts
Premergy, Inc.	Owner of more than 5%	Alpharetta, GA	30,000,000	Common	75.08%	Richard Botts
GoLanier.Com, Inc. and Denson Street Technologies, Inc.	Owners of more than 5%	Alpharetta, GA	3,046,075 Beneficially owned as shareholders of Premergy	Common	7.62%	Lanier Davenport

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

 Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Michael A. Littman, Esq.
Address 1: 7609 Palston Rd

 Address 1:
 7609 Ralston Rd.

 Address 2:
 Arvada, CO 80002

 Phone:
 (720) 530-6184

 Email:
 malatty@aol.com

	Accountant or Audi	<u>tor</u>
	Name: Firm: Address 1 Address 2: Phone: Email: Investor Relations Name: Firm:	None
	Address 1: Address 2: Phone: Email:	
	All other means of I	Investor Communication:
	X (Twitter): Discord: LinkedIn Facebook: [Other]	
	provided informate broker-dealer(s), acception services to the issue Name: David R. Be Firm: DRB Consulti	of any other service provider(s) that that assisted , advised , prepared , or cion with respect to this disclosure statement . This includes counsel, dvisor(s), consultant(s) or any entity/individual that provided assistance or er during the reporting period. Channa, CPA Ing Inc. Accounting and Consulting appropriate properties and consulting appropriate prove, NY 11755 725
	Disclosure & Financial	Information
A.	This Disclosure Statement Name: Title: Relationship to Issuer:	ent was prepared by (name of individual): David R Behanna, CPA Accountant Consultant
B.	The following financial s ☐ IFRS ☐ U.S. GAAP	tatements were prepared in accordance with:
C.	The following financial s	tatements were prepared by (name of individual):
	Name: Title: Relationship to Issuer:	David R Behanna, CPA Accountant Consultant

9)

Describe the qualifications of the person or persons who prepared the financial statements: 5 CPA

Provide the following qualifying financial statements:

- Audit letter, if audited;
- o Balance Sheet:
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

- I, William Hayde certify that:
 - 1. I have reviewed this Disclosure Statement for Innovative Holdings Alliance, Inc.;
 - Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
 - 3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

September 12, 2024 [Date]

/s/ William Hayde [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

⁵ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

Principal Financial Officer:

I, William Hayde certify that:

- 1. I have reviewed this Disclosure Statement for Innovative Holdings Alliance, Inc.;
- Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
- Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

September 12, 2024 [Date]

/s/ William Hayde [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]

Innovative Holdings Alliance, Inc. Consolidated Financial Statements May 31, 2024 and 2023 (Unaudited)

Innovative Holdings Alliance, Inc. Index to Consolidated Financial Statements May 31, 2024 and 2023

	Page Number
Consolidated Balance Sheets	1
Consolidated Statements of Operations	2
Consolidated Statements of Stockholders' (Deficit)	3
Consolidated Statements of Cash Flows	4
Notes to Consolidated Financial Statements	5-14

INNOVATIVE HOLDINGS ALLIANCE, INC. and SUBSIDIARY CONSOLIDATED BALANCE SHEETS

MAY 31, 2024 AND 2023

(Unaudited)

	2024		2023		
ASSETS		_			
CURRENT ASSETS					
Cash	\$	2,674	\$	6,708	
Prepaid expenses		5,445		4,800	
Deposit		10,501		5,000	
TOTAL CURRENT ASSETS		18,620		16,508	
FIXED ASSETS					
Property and equipment, net		76,043		-	
TOTAL FIXED ASSETS		76,043		-	
OTHER ASSETS					
Intangible assets, net of accumulated amortization		8,033,699		67,188	
TOTAL OTHER ASSETS		8,033,699		67,188	
TOTAL ASSETS	\$	8,128,362	\$	83,696	
LIABILITIES AND STOCKHOLDERS' (DEFICURRENT LIABILITIES	ICIT)				
Accounts payable and accrued expenses	\$	311,042	\$	53,537	
Note payable	Ψ	511,042	Ψ	1,500	
Due to shareholder		-		22,904	
Convertible notes payable					
TOTAL CURRENT LIABILITIES	1,048,458				
Commitments (Note 9)					
STOCKHOLDERS' (DEFICIT)					
Series A Preferred shares, \$.001 par value, 500,000 shares authorized;					
0 and 500 shares issued and outstanding at May 31, 2024 and 2023, respectively		-		1	
Series B Convertible shares, \$.001 par value, 500,000 shares authorized;					
0 shares issued and outstanding Common shares, \$.001 par value, 500,000,000 shares authorized, 39,955,427 and		-		-	
17,155,427 shares issued and outstanding at May 31, 2024 and 2023, respectively		39,955		17,155	
Additional paid-in-capital		8,946,353		1,031,652	
Accumulated (deficit)		(1,906,404)		(1,353,053)	
TOTAL STOCKHOLDERS' (DEFICIT)		7,079,904		(304,245)	
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)	\$	8,128,362	\$	83,696	

INNOVATIVE HOLDINGS ALLIANCE, INC. and SUBSIDIARY CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED MAY 31, 2024 AND 2023 (Unaudited)

	 2024	2023		
REVENUE	\$ -	\$	-	
OPERATING EXPENSES	278,600		146,609	
(LOSS) FROM OPERATIONS	(322,787)		(146,609)	
OTHER (EXPENSES)				
Loss on impairment of intellectual property	(229,520)		-	
Interest Expense	(45,231)		(23,216)	
(LOSS) BEFORE PROVISION FOR INCOME TAXES	(553,351)		(169,825)	
Provision For Income Taxes	-		-	
NET (LOSS)	\$ (553,351)	\$	(169,825)	
WEIGHTED AVERAGE NUMBER OF COMMON SHARES:				
Basic	 26,110,222		16,884,960	
Fully Diluted	 61,348,578		40,118,476	

INNOVATIVE HOLDINGS ALLIANCE, INC. and SUBSIDIARY CONSOLIDATED STATEMENT OF STOCKHOLDERS' (DEFICIT) FOR THE YEARS ENDED MAY 31, 2024 AND 2023

(Unaudited)

	Series A Pre \$.001 P	ferred Sl ar Value		Series B Prefe \$.001 Par		es	Common \$.001 Pa		Additional Paid In	A	ccumulated	Sto	Total
	Shares	Ar	nount	Shares	Amo	unt_	Shares	 Amount	 Capital		(Deficit)		(Deficit)
BALANCES, May 31, 2022	500	\$	1	-	\$	-	16,980,427	\$ 16,980	\$ 956,827	\$	(1,183,228)	\$	(209,420)
Issuance of common stock	-		-	-		-	375,000	375	74,625		-		75,000
Return of common stock	-		-	-		-	(200,000)	(200)	200		-		-
Net (loss)	-		-			-		 -			(169,825)		(169,825)
BALANCES, May 31, 2023	500	\$	1	-	\$	-	17,155,427	\$ 17,155	\$ 1,031,652	\$	(1,353,053)	\$	(304,245)
Return of preferred stock	(500)		(1)	-		-	-	-	1		-		-
Return of common stock	-		-	-		-	(8,950,000)	(8,950)	8,950		-		-
Common shares issued related to the Premergy acquisition	-		-	-		-	31,500,000	31,500	7,843,500		-		7,875,000
Issuance of shares for services	-		-	-		-	250,000	250	62,250		-		62,500
Net (loss)	-					-		 -	 <u>-</u>		(553,351)		(553,351)
BALANCES, May 31, 2024	-	\$	-	<u>-</u>	\$	-	39,955,427	\$ 39,955	\$ 8,946,353	\$	(1,906,404)	\$	7,043,885

INNOVATIVE HOLDINGS ALLIANCE, INC. and SUBSIDIARY CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEARS ENDED MAY 31, 2024 AND 2023 (Unaudited)

(Onaudica)					
		2024		2023	
Cash flows from operating activities:					
Net (loss)	\$	(553,351)	\$	(169,825)	
Amortization of intangible asset		37,500		7,812	
Depreciation		5,941		-	
Issuance of shares for services		62,500		-	
Write-off of shareholder loan		(22,904)		-	
Adjustments to reconcile net loss) to net cash flows					
used in operating activities;					
Decrease in prepaid expenses		(645)		13	
Loss on impairment of intellectual property		229,520		-	
Increase in deposit		(5,501)		(5,000)	
Increase in accounts payable and accrued expenses		149,505		31,716	
Net cash (used) in operating activities		(97,435)		(135,284)	
Cash flows from investing activities:					
Acquisition of property and equipment		(247)		-	
Addition to intellectual property		(59,852)			
Net cash provided by financing activities		(60,099)	-		
Cash flows from financing activities:					
Proceeds from convertible notes payable		155,000		140,000	
Repayment of notes payable		(1,500)		-	
Net cash provided by financing activities		153,500		115,000	
Net increase (decrease) in cash		(4,034)		4,716	
Cash at beginning of the period		6,708		1,992	
Cash at end of the period	\$	2,674	\$	6,708	
Supplemental Disclosures:					
Issuance of common stock for the intangible asset	\$	-	\$	75,000	
Cash paid during the period for: Interest	\$	_	\$	_	
Non-cash investing activities:	Ψ		Ψ		
Common shares issued related to the Premergy acquisition	\$	7,875,000	\$	-	

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and Nature of Operations

Innovative Holdings Alliance, Inc. ("IHAI" or "the Company") was organized on February 24, 2011 under the laws of the State of Delaware. The Company has had no operations since April 2017.

IHAI Brands, Inc. ("IHAIB") was organized on March 13, 2023 under the laws of the State of Delaware as a wholly-owned subsidiary of IHAI for the sole purpose of entering into the brand licensing agreement as more fully described in NOTE 4.

Basis of Presentation and Consolidation

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. Estimates include the valuation on deferred tax assets and valuation of stock issued for services. Actual results could differ from those estimates.

Cash and Cash Equivalents

IHAI considers all highly liquid cash investments with an original maturity of twelve months or less to be cash equivalents.

Property and Equipment

Property and equipment is stated at cost. Maintenance and repairs are expensed as incurred. Upon sale or disposition of assets, any gain or loss in included in the consolidated financial statements of operations. The cost of property and equipment is depreciated using the straight line method over the estimated useful lived of the assets when placed in service, which range from five to ten years.

Intellectual Property

The Company's intangible assets consist of patents on its technology, recorded at cost. Cost is based on third party expenditures for patent acquisitions and applications. IHAI will begin amortizing the intangibles over their estimated remaining useful life when it begins revenue-producing activities. IHAI will determine the useful lives of its intangible assets after considering the specific facts and circumstances related to each intangible asset. Factors that will be considered when determining useful lives include the contractual term of any agreement related to the asset, the historical performance of the asset, the long-term strategy for using the asset, any laws or other local regulations could impact the useful life of the asset, and other economic factors, including competition and specific market conditions.

Impairment of Long-lived Assets

Potential impairments of long-lived assets are reviewed when events or changes in circumstances indicate a potential impairment may exist. In accordance with ASC 360-10, "Property, Plant and Equipment – Overall", impairment is determined when estimated future undiscounted cash flows associated with an asset are less than the asset's carrying value. The reserve for impairment for obsolescence as of May 31, 2024 and 2023 was \$234,569 and \$0, respectively.

Stock Based Compensation Expense

The Company records stock-based compensation in accordance with the provisions of FASB ASC 718, "Accounting for Stock Compensation," which establishes accounting standards for transactions in which an entity exchanges its equity instruments for goods or services. In accordance with guidance provided under ASC Topic 718, the Company recognizes an expense for the fair value of its stock awards at the time of grant and the fair value of its outstanding stock options as they vest, whether held by employees or others. As of May 31, 2024 and 2023, there were no options outstanding.

Convertible Debentures

The Company adopted the guidance in Accounting Standards Updated ("ASU") 2020-06, "Accounting for Convertible Instruments and Contracts in an Entity's Own Equity" on January 1, 2022. ASU 2020-06 simplifies an issuer's accounting for convertible instruments and its application of the derivatives scope exception for contracts in its own equity. Additionally, ASU 2020-06 removes the requirements for accounting for beneficial conversion features. The Company adopted ASU 2020-06 utilizing the modified retrospective method, which resulted in an immaterial impact to the Company.

Income Taxes

The Company has adopted Financial Accounting Standards Board ("FASB") Account Standards Codification ("ASC") 740-10, "Accounting for Income Taxes", which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually from differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. The Company's federal tax return and any state tax returns are not currently under examination.

Going Concern

As of May 31, 2024, the Company has minimal assets, accumulated operating losses of \$1,906,404 since its inception in February of 2011 and no revenues between April 2017 and May 2024, all of which raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. However, the Company is currently addressing its liquidity issues by continually seeking investment capital through private placement of common stock and debt. Issuances of additional shares will result in dilution to our existing stockholders. There is no assurance that we will be able to complete any additional sales of our equity securities or that we will be able to arrange for other financing to fund our planned business activities.

NOTE 2 – PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at May 31:

	 2024	2	2023
Equipment	\$ 9,681	\$	-
Vehicle	72,303		
	81,984		-
Less: Accumulated Depreciation	 (5,941)		
	\$ 76,043	\$	-

Depreciation expense for the year ended May 31, 2024 was \$5,941.

NOTE 3 – PURCHASE OF ASSETS FROM PREMERGY, INC.

On December 30, 2023 ("Closing Date"), the Company acquired all the operational assets of Premergy, Inc. ("Premergy") by issuing 30,000,000 shares of restricted common stock to Premergy valued at \$7,500,000, or \$.25 per share, which was net of a 40% discount off the publically quoted price of the Company's common stock of approximately \$.42 per share on December 29, 2023. The issuance of these shares resulted in Premergy owning approximately 37% of IHAI on a fully-diluted basis on the Closing Date. The Company also assumed accounts payable and notes payable from Premergy in the amount of \$108,000 and \$272,416, respectively. The notes payable were formalized through the issuance of convertible promissory notes by IHAI dated January 11, 2024. These convertible notes provide for interest at 7.5% per annum, have a two year term and are convertible after one year into IHAI common stock at \$.50 per share or a 20% discount to market per share, whichever is greater. The total consideration to the benefit of Premergy for this transaction was \$7,880,416.

In addition, the Company issued 1,500,000 shares of restricted common stock for legal fees and consulting services directly plus \$25,000 for legal fees directly related to assisting with negotiating and closing of the above transaction. The shares were valued at \$375,000, or \$.25 per share (the same as above). This share value plus the \$25,000 was capitalized as an additional cost to acquire the assets of Premergy.

The fair-market-value of the assets acquired from Premergy was \$25,000,000 for patents and \$250,000 for physical assets. Based these fair-market-values, the total acquisition cost of \$8,280,416 was allocated on a pro-rata basis that resulted in a value for the patents of \$8,198,432 and a value for the physical assets of \$81,984 records on the books of IHAI.

NOTE 4 – INTANGIBLE ASSET

On March 14, 2023, IHAIB ("Licensee") entered into a licensing agreement with M2Bio Sciences Food and Beverage, Ltd, a South African company, ("the Licensor") to market products in the United States on a non-exclusive basis under the Dr.AnnaRx, Medspresso and Liviana trademarked brands ("Licensed Products") for \$75,000. This agreement has an initial term of two years and will automatically renew for successive one year terms unless extended by mutual agreement or terminated in writing, by either party, at least sixty (60) days prior to the end of the current term. In addition, IHAIB was required to start marketing the Licensed Products on March 31, 2023 through Licensor approved sales channels at wholesale and retail pricing agreed upon by the parties on a quarterly basis. The \$75,000 license fee was paid for by IHAI issuing 375,000 shares of restricted common stock valued at \$.20 per share. This fee is being amortized on a straight-line basis over the initial two year term of the agreement. The amortization expense was \$37,500 and \$7,813 for the years ended May 31, 2024 and 2023, respectively, and is included in operating expenses.

Intellectual property at May 31, 2024 and 2023 in the amounts of \$8,004,200 and \$0 are presented net of impairment reserves of \$229,519 and \$0, respectively. The intellectual property includes patents of systems, methods and apparatus for various generator chargers, as well as technology for battery charging and power management, adaptive regeneration systems for electric vehicles, dynamic control of configuration of electrical systems, control schemes and intelligent battery selection for electric vehicles, electric vehicles, intelligent circuit control for solar panel systems, and battery systems for electric vehicles, that were acquired on January 11, 2024 as part of the asset acquisition from Premergy, plus legal fees subsequently incurred directly related to these patents and additional patent applications. The Company recognized impairment of value of the patents of \$229,519 and \$0 for the year ended May 31, 2024 and 2023, respectively.

NOTE 5 – CAPITAL STOCK

Preferred Shares

The authorized preferred stock of the Company consists of 20,000,000 shares, \$.001 par value. The preferred stock may be issued in separate series from time to time as the Board of Directors of the Company may determine by resolution, unless the nature of a particular transaction and applicable statutes require shareholder approval. The rights, preferences and limitations of each series of preferred stock may differ, including without limitation, the rate of dividends, method and nature of payment of dividends, terms of redemption, amounts payable on liquidation, sinking fund provisions (if any) conversion rights (if any) and voting rights.

Series A Preferred Stock

In connection with an amendment to the articles of incorporation of the Company, the Company authorized 500,000 shares of \$.001 par value Series A Preferred Stock ("Series A Stock"). The Series A Stock are entitled to no dividends and the Company has no redemptive right. The holders of the Series A Stock have the right to vote on any matter and the holders of the shares shall have the number of votes equal to that number of common shares which is not less than 60% of the vote required to approve any action. The Company had no shares of Series A Stock issued and outstanding as of May 31, 2024. (See Note 10)

Series B Preferred Convertible Stock

In connection with an amendment to the articles of incorporation of the Company, the Company authorized 500,000 shares of \$.001 par value Series B Preferred Convertible Stock ("Series B Stock"). At the option of the holder, the shares are convertible into 100 shares of common stock for each share of Series B Stock. The holders of such Series B Stock are entitled to receive cumulative cash dividends equal to 15% of the issue price per share, payable quarterly beginning September 30, 2011 and continuing until the Series B Stock is redeemed or converted. In the event that the dividends are not paid in any period, the dividends accumulate and must be paid prior to dividends on the common stock or any other class of stock junior to the Series B Stock, except for the Series A Stock. The Company had no shares of Series B Stock issued and outstanding as of May 31, 2024 and, therefore, no dividends have been accrued.

Common Stock

IHAI is authorized to issue 500,000,000 shares of \$.001 voting common stock. The Company had 39,955,427 and 17,155,427 shares of common stock issued and outstanding as of May 31, 2024 and 2023, respectively.

NOTE 6 – RELATED PARTY TRANSACTIONS

Due to Shareholder

A shareholder of IHAI, who was also the former President and CEO, had advanced funds to the Company to support operations through April 2017 totaling \$22,904. This balance was written-off during the year ended May 31, 2024 pursuant to his agreement with the Company.

Management Fees

Beginning in March 2021, the former President and CEO of the Company was entitled to receive monthly payments of \$5,000 for management services. Payments were made on a month-to-month basis, subject to cash availability. This agreement was replaced on January 17, 2024 with a new Corporate Services Agreement (see Note 10) and the outstanding balance due the former President and CEO pursuant to his previous agreement was written-off during the year ended May 31, 2024.

NOTE 7 – NOTE PAYABLE

On March 8, 2021, the Company received financing from an unrelated party for \$1,500 to cover various operating expenses. This note is non-interest bearing and is payable upon demand. On October 24, 2023 the Company repaid \$500 of this note. The remaining balance of \$1,000 was paid off on April 8, 2024.

NOTE 8 – CONVERTIBLE NOTES PAYABLE

On March 23, 2021, the Company issued a convertible note to an unrelated party for \$30,000 that matured on September 30, 2021. Interest accrues and is payable on the first day of each calendar month at a rate of 10% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share through the maturity date. Interest expense for this convertible note was \$3,008 for the year ended May 31, 2024. This note was not converted by the note holder or paid by the Company prior to the September 30, 2021 maturity date. However, on October 11, 2021 the note holder granted an extension of the maturity date to December 31, 2021 and also agreed this note was not in default. This note was not converted by the note holder or paid by the Company prior to the December 31, 2021 extended maturity date. However, on January 7, 2022 the note holder granted an additional extension of the maturity date to September 30, 2022 and also agreed this note was not in default. This note was not converted by the note holder or paid by the Company prior to the September 30, 2022 extended maturity date. However, on October 11, 2022 the note holder granted an additional extension of the maturity date to March 31, 2023 and also agreed this note was not in default. This note was not converted by the note holder or paid by the Company prior to the March 31, 2023 extended maturity date. However, on July 26, 2023 the note holder granted an additional extension of the maturity date to March 31, 2024 and also agreed this note was not in default. This note was not converted by the note holder or paid by the Company prior to the March 31, 2024 extended maturity date. However, on March 31, 2024 the note holder granted an additional extension of the maturity date to September 23, 2024 and also agreed this note was not in default. This note has not been converted by the note holder or paid by the Company. However, on September 9, 2024 the note holder granted an additional extension of the maturity date to March 25, 2025 and also agreed this note was not in default. All other terms of this convertible note agreement remained the same.

On March 23, 2021, the Company issued a convertible note to an unrelated party for \$20,000 that matured on April 13, 2022. Interest accrues and is payable on the first day of each calendar month at a rate of 10% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share through the maturity date. Interest expense for this convertible note was \$2,005 for the year ended May 31, 2024. This note was not converted by the note holder or paid by the Company prior to the April 13, 2022 maturity date. However, on April 7, 2022 the note holder granted an extension of the maturity date to September 30, 2022 and also agreed this note was not in default. This note was not converted by the note holder or paid by the Company prior to the September 30, 2022 extended maturity date. However, on October 11, 2022 the note holder granted an additional extension of the maturity date to March 31, 2023 and also agreed this note was not in default. This note was not converted by the note holder or paid by the Company prior to the March 31, 2023 extended maturity date. However, on June 27, 2023 the note holder granted an additional extension of the maturity date to October 31, 2023 and also agreed this note was not in default. However, on January 9, 2024 the note holder granted an additional extension of the maturity date to December 31, 2024 and also agreed this note was not in default. All other terms of this convertible note agreement remained the same.

On June 7, 2021, the Company issued a convertible note to an unrelated party for \$30,000 that matured on December 31, 2021. Interest accrues and is payable on the first day of each calendar month at a rate of 10% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share through the maturity date. Interest expense for this convertible note was \$3,008 for the year ended May 31, 2024. This note was not converted by the note holder or paid by the Company prior to the December 31, 2021 maturity date. However, on January 7, 2022 the note holder granted an extension of the maturity date to September 30, 2022 and also agreed this note was not in default. This note was not converted by the note holder or paid by the Company prior to the September 30, 2022 extended maturity date. However, on October 11, 2022 the note holder granted an additional extension of the maturity date to March 31, 2023 and also agreed this note was not in default. This note was not converted by the note holder or paid by the Company prior to the March 31, 2023 extended maturity date. However, on July 26, 2023 the note holder granted an additional extension of the maturity date to March 31, 2024 and also agreed this note was not in default. This note was not converted by the note holder or paid by the Company prior to the March 31, 2024 extended maturity date. However, on March 31, 2024 the note holder granted an additional extension of the maturity date to September 7, 2024 and also agreed this note was not in default. This note was not converted by the note holder or paid by the Company prior to the September 7, 2024 extended maturity date. However, on September 7, 2024 the note holder granted an additional extension of the maturity date to March 7, 2025 and also agreed this note was not in default. All other terms of this convertible note agreement remained the same.

On August 27, 2021, the Company issued a convertible note to an unrelated party for \$40,000 that matured on August 27, 2022. Interest accrues and is payable on the first day of each calendar month at a rate of 10% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share through the maturity date. Interest expense for this convertible note was \$4,011 for the year ended May 31, 2024. This note was not converted by the note holder or paid by the Company prior to the August 27, 2022 maturity date. However, on September 8, 2022 the note holder granted an extension of the maturity date to February 27, 2023. This note was not converted by the note holder or paid by the Company prior to the February 27, 2023 extended maturity date. However, on March 1, 2023 the note holder granted an additional extension of the maturity date to August 31, 2023 and also agreed this note was not in default. This note was not converted by the note holder granted an additional extension of the maturity date to February 28, 2024 and also agreed this note was not in default. All other terms of this convertible note agreement remained the same.

On October 28, 2021, the Company issued a convertible note to an unrelated party for \$25,000 that matured on October 28, 2022. Interest accrues and is payable on the first day of each calendar month at a rate of 10% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share through the maturity date. Interest expense for this convertible note was \$2,507 for the year ended May 31, 2024. This note was not converted by the note holder or paid by the Company prior to the October 28, 2022 maturity date.

However, on January 7, 2023 the note holder granted an extension of the maturity date to March 31, 2023 and also agreed this note was not in default. This note was not converted by the note holder or paid by the Company prior to the March 31, 2023 maturity date. However, on March 13, 2023 the note holder granted an additional extension of the maturity date to February 28, 2024 and also agreed this note was not in default. This note was not converted by the note holder or paid by the Company prior to the February 28, 2024 extended maturity date. However, on February 28, 2024 the note holder granted an additional extension of the maturity date to August 31, 2024 and also agreed this note was not in default. This note was not converted by the note holder or paid by the Company prior to the August 31, 2024 extended maturity date. However, on August 31, 2024 the note holder granted an additional extension of the maturity date to February 27, 2025 and also agreed this note was not in default. All other terms of this convertible note agreement remained the same.

On March 30, 2022, the Company issued a convertible note to an unrelated party for \$25,000 that matured on March 30, 2023. Interest accrues and is payable on the first day of each calendar month at a rate of 10% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share through the maturity date. Interest expense for this convertible note was \$2,507 for the year ended May 31, 2024. This note was not converted by the note holder or paid by the Company prior to the March 30, 2023 maturity date. However, on July 26, 2023 the note holder granted an extension of the maturity date to March 30, 2024 and also agreed this note was not in default. This note was not converted by the note holder or paid by the Company prior to the March 30, 2024 and also agreed this note was not in default. This note has not been converted by the note holder or paid by the Company. However, on September 9, 2024 the note holder granted an additional extension of the maturity date to March 30, 2025 and also agreed this note was not in default. All other terms of this convertible note agreement remained the same.

On July 14, 2022, the Company issued a convertible note to an unrelated party for \$35,000 that matured on July 14, 2023. Interest accrues and is payable on the first day of each calendar month at a rate of 10% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share through the maturity date. Interest expense for this convertible note was \$3,510 for the year ended May 31, 2024. This note was not converted by the note holder or paid by the Company prior to the July 14, 2023 maturity date. However, on July 14, 2023 the note holder granted an extension of the maturity date to January 14, 2024 and also agreed this note was not in default. This note was not converted by the note holder or paid by the Company prior to the January 14, 2024 maturity date. However, on January 9, 2024 the note holder granted an additional extension of the maturity date to December 31, 2024 and also agreed this note was not in default. All other terms of this convertible note agreement remained the same.

On November 15, 2022, the Company issued a convertible note to an unrelated party for \$35,000 that matured on November 15, 2023. Interest accrues and is payable on the first day of each calendar month at a rate of 10% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share through the maturity date. Interest expense for this convertible note was \$3,510 for the year ended May 31, 2024. This note was not converted by the note holder or paid by the Company prior to the November 15, 2023 maturity date. However, on January 9, 2024 the note holder granted an extension of the maturity date to December 31, 2024 and also agreed this note was not in default. All other terms of this convertible note agreement remained the same.

On March 14, 2023, the Company issued a convertible note to an unrelated party for \$50,000 that matured on March 14, 2024. Interest accrues and is payable on the first day of each calendar month at a rate of 10% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share through the maturity date. Interest expense for this convertible note was \$5,014 for the year ended May 31, 2024. This note was not converted by the note holder or paid by the Company prior to the March 14, 2024 maturity date. However, on March 14, 2024 the note holder granted an extension of the maturity date to September 14, 2024 and also agreed this note was not in default. This note has not been converted by the note holder or paid by the Company. However, on September 9, 2024 the note holder granted an extension of the maturity date to March 14, 2025 and also agreed this note was not in default. All other terms of this convertible note agreement remained the same.

On April 28, 2023, the Company issued a convertible note to an unrelated party for \$20,000 that matured on April 29, 2024. Interest accrues and is payable on the first day of each calendar month at a rate of 10% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share through the maturity date. Interest expense for this convertible note was \$2,005 for year ended May 31, 2024. This note was not converted by the note holder or paid by the Company prior to the April 29, 2024 maturity date. However, on April 28, 2024 the note holder granted an extension of the maturity date to October 28, 2024 and also agreed this note was not in default. All other terms of this convertible note agreement remained the same.

On August 31, 2023, the Company issued a convertible note to an unrelated party for \$25,000 that matures on August 31, 2024. Interest accrues and is payable on the first day of each calendar month at a rate of 12% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.05 per share through the maturity date. Interest expense for this convertible note was \$2,252 for the year ended May 31, 2024. This note was not converted by the note holder or paid by the Company prior to the August 31, 2024 maturity date. However, on August 31, 2024 the note holder granted an extension of the maturity date to February 28, 2025 and also agreed this note was not in default. All other terms of this convertible note agreement remained the same.

On January 11, 2024, the Company issued a convertible note to an unrelated party for \$100,000 that matures on January 11, 2025. Interest accrues and is payable on the first day of each calendar month at a rate of 10% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share through the maturity date. Interest expense for this convertible note was \$3,863 for the year ended May 31, 2024.

On January 11, 2024, as a result of the asset purchase agreement, the Company issued a convertible note to an unrelated party for \$25,576 that matures on January 11, 2026. Interest accrues and is payable upon its maturity at a rate of 7% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time after twelve months of issuance, in whole or in part, into shares of restricted common stock at a rate of \$.50 per share through the maturity date. Interest expense for this convertible note was \$692 for the year ended May 31, 2024.

On January 11, 2024, as a result of the asset purchase agreement, the Company issued a convertible note to an unrelated party for \$2,000 that matures on January 11, 2026. Interest accrues and is payable upon its maturity at a rate of 7% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time after twelve months of issuance, in whole or in part, into shares of restricted common stock at a rate of \$.50 per share through the maturity date. Interest expense for this convertible note was \$54 for the year ended May 31, 2024.

On January 11, 2024, as a result of the asset purchase agreement, the Company issued a convertible note to an unrelated party for \$44,500 that matures on January 11, 2026. Interest accrues and is payable upon its maturity at a rate of 7% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time after twelve months of issuance, in whole or in part, into shares of restricted common stock at a rate of \$.50 per share through the maturity date. Interest expense for this convertible note was \$1,203 for the year ended May 31, 2024.

On January 11, 2024, as a result of the asset purchase agreement, the Company issued a convertible note to an unrelated party for \$2,340 that matures on January 11, 2026. Interest accrues and is payable upon its maturity at a rate of 7% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time after twelve months of issuance, in whole or in part, into shares of restricted common stock at a rate of \$.50 per share through the maturity date. Interest expense for this convertible note was \$63 for the year ended May 31, 2024.

On January 11, 2024, as a result of the asset purchase agreement, the Company issued a convertible note to an unrelated party for \$188,000 that matures on January 11, 2026. Interest accrues and is payable upon its maturity at a rate of 7% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time after twelve months of issuance, in whole or in part, into shares of restricted common stock at a rate of \$.50 per share through the maturity date. Interest expense for this convertible note was \$5,084 for the year ended May 31, 2024.

On January 11, 2024, as a result of the asset purchase agreement, the Company issued a convertible note to an unrelated party for \$10,000 that matures on January 11, 2026. Interest accrues and is payable upon its maturity at a rate of 7% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time after twelve months of issuance, in whole or in part, into shares of restricted common stock at a rate of \$.50 per share through the maturity date. Interest expense for this convertible note was \$270 for the year ended May 31, 2024.

On February 20, 2024, the Company issued a convertible note to an unrelated party for \$30,000 that matures on February 20, 2025. Interest accrues and is payable on the first day of each calendar month at a rate of 8% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time after six months of issuance, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share through the maturity date. Interest expense for this convertible note was \$664 for the year ended May 31, 2024.

NOTE 9 – INCOME TAXES

As of May 31, 2024, the Company had a net operating loss carry forward of approximately \$1,906,000 that may be available to reduce future years' taxable income in varying amounts through 2038. Future tax benefits which may arise as a result of these losses have not been recognized in these consolidated financial statements, as their realization is determined not likely to occur and, accordingly, the Company has recorded a full valuation allowance equal to the deferred tax asset relating to this tax loss carry-forward of approximately \$400,000 as of May 31, 2024.

The Company periodically evaluates the likelihood of the realization of deferred tax assets, and adjusts the carrying amount of the deferred tax assets by the valuation allowance to the extent the future realization of the deferred tax assets is not judged to be more likely than not. The Company considers many factors when assessing the likelihood of future realization of its deferred tax assets, including its recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carryforward periods available to the Company for tax reporting purposes, and other relevant factors.

Future changes in the unrecognized tax benefit will have no impact on the effective tax rate due to the existence of the valuation allowance. The Company estimates that the unrecognized tax benefit will not change significantly within the next twelve months. The Company will continue to classify income tax penalties and interest as part of general and administrative expense in its consolidated statements of operations and comprehensive loss. There were no interest or penalties accrued as of May 31, 2024.

NOTE 10 - COMMITMENTS

On January 16, 2024, M. Chris Winter ("Winter") resigned from all Officer and Director positions of IHAI. Winter also agreed to the cancellation of his 500 shares of Series A Preferred Stock and the cancellation of 8,950,000 shares of Common Stock, leaving 1,000,000 shares of common stock held in his name personally.

On January 16, 2024, IHAI entered into an Employment Agreement (the "Agreement") with William Hayde ("Hayde") and appointed him Chief Executive Officer ("CEO"). The Agreement has an initial term of one year. No less than thirty (30) days prior to the expiration of the initial term, the Company and Hayde shall review the terms of employment and the Company shall provide Hayde with the terms upon which the employment may be renewed or with a notice of non-renewal. Hayde's base salary during the initial term is \$60,000, payable in accordance with the Company's standard payroll policies in effect, plus additional employee benefits offered by the Company. In addition to the Agreement, Hayde also received 250,000 restricted shares of IHAI common stock valued at \$62,500, or \$.25 per share. The \$62,500 was expensed as officer compensation for the year ended May 31, 2024.

On January 16, 2024, IHAI entered into an Employment Agreement (the "Agreement") with Richard Botts ("Botts") and appointed him Chief Technology Officer ("CTO"). The Agreement has an initial term of one year. No less than thirty (30) days prior to the expiration of the initial term, the Company and Botts shall review the terms of employment and the Company shall provide Botts with the terms upon which the employment may be renewed or with a notice of non-renewal. Botts's base salary during the initial term is \$42,000, payable in accordance with the Company's standard payroll policies in effect, plus additional employee benefits offered by the Company.

On January 17, 2024, IHAI entered into a Corporate Services Agreement (the "Agreement") with an entity that is beneficially owned and managed by the former CEO of IHAI. The Agreement authorizes the consultant to provide certain transitional corporate services to the Company's newly appointed officers, directors and others on an as needed, non-exclusive, basis for a term of one year. As compensation for providing the services, the Company agreed to pay the consultant \$5,000 per month during the term of the Agreement beginning February 1, 2024. The Agreement can be terminated upon thirty (30) days written notice by either party. Either party can also terminate the Agreement at any time for cause as defined.

On January 22, 2024, IHAI entered into a Corporate Services Agreement (the "Agreement") with an independent third-party to provide certain corporate services to assist the Company's business development efforts related to its battery charging technology on an as needed, non-exclusive, basis for an initial term of one year. This Agreement automatically renew for successive one year terms, unless terminated by either party by providing thirty (30) day advance written notice. Either party can also terminate the Agreement at any time for cause as defined. As compensation for providing the services, the Company agreed to pay the consultant \$15,000 per month during the term of the Agreement beginning January 1, 2024. In addition to the Agreement, the consultant also received 1,000,000 restricted shares of IHAI common stock valued at \$250,000, or \$.25 per share, for consulting services directly related to assisting with negotiating and closing the Premergy's transaction. As such, the \$250,000 was capitalized as an additional cost to acquire the assets of Premergy.

NOTE 11 – SUBSEQUENT EVENTS

On June 10, 2024, the Company issued a convertible note to an unrelated party for \$20,000 that matures on June 10, 2025. Interest accrues monthly and is payable upon maturity at a rate of 8% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time after six months of issuance, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share through the maturity date.

On June 20, 2024, the Company issued a convertible note to an unrelated party for \$25,000 that matures on June 20, 2025. Interest accrues monthly and is payable upon maturity at a rate of 8% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time after six months of issuance, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share through the maturity date.

Effective July 1, 2024, the Company entered into a lease for virtual office space through December 31, 2004 with an initial base rent of \$59 per month. This lease automatically renews at the end of each calendar year with a base rent of \$70 per month and may be cancelled at any time upon 30 days advance written notice after the initial lease term.

On July 9, 2024, the Company issued a convertible note to an unrelated party for \$25,000 that matures on July 9, 2025. Interest accrues monthly and is payable upon maturity at a rate of 8% per annum on the unpaid balance. This note is convertible at the sole discretion of the holder at any time after six months of issuance, in whole or in part, into shares of restricted common stock at a rate of \$.01 per share through the maturity date.

Management has evaluated subsequent events through September 11, 2024, the date the financial statements were available to be issued, and has determined that there are no other events that would require an adjustment to, or disclosure in, the financial statements as of May 31, 2024.